Professor Dr. John Kastelein is founder and Chief Scientific Officer of NewAmsterdam Pharma and a member of the Executive Board. Prof. Dr. Kastelein is Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, where he held the office of Strategic Chair of Genetics of Cardiovascular Disease. Prof. Dr. Kastelein has published more than 1,320 research papers in peer-reviewed journals, including Nature Genetics, The Lancet, New England Journal of Medicine, JAMA, and Circulation, with a Hirsch index of 162. His research has been cited more than 90,000 times. Prof. Dr. Kastelein is a member of the steering committees of numerous lipid-lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for cardiovascular diseases and the genetic basis of dyslipidemia. Prof. Dr. Kastelein is CEO of the Vascular Research Network, a site maintenance organization comprised of 50 hospitals in the Netherlands, involved in clinical trials for cardiometabolic disease. He is president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and a Fellow of the European Society of Cardiology. In 2010, he was awarded the prestigious Dutch Heart Association award of €1 million, and, in 2011, he was awarded the ZonMw Parel for his research in the field of gene therapy. Additionally, Prof. Dr. Kastelein is key advisor to a number of biotech and pharmaceutical companies. Prof. Dr. Kastelein earned his doctorate in medicine with honors from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver.